Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

Rossi, Niccolò; Lee, Karla A; Bermudez, Maria V; Visconti, Alessia; Thomas, Andrew Maltez; Bolte, Laura A; Björk, Johannes R; de Ruijter, Laura Kist; Newton-Bishop, Julia; Harland, Mark; Shaw, Heather M; Harries, Mark; Sacco, Joseph; Board, Ruth; Lorigan, Paul; de Vries, Elisabeth G E; Segata, Nicola; Taams, Leonie; Papa, Sophie; Spector, Tim D; Nathan, Paul; Weersma, Rinse K; Hospers, Geke A P; Fehrmann, Rudolf S N; Bataille, Veronique; Falchi, Mario

doi:10.1016/j.ebiom.2022.104235

Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor (ICI) therapy for advanced melanoma.

Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma / Rossi, Niccolò; Lee, Karla A; Bermudez, Maria V; Visconti, Alessia; Thomas, Andrew Maltez; Bolte, Laura A; Björk, Johannes R; de Ruijter, Laura Kist; Newton-Bishop, Julia; Harland, Mark; Shaw, Heather M; Harries, Mark; Sacco, Joseph; Board, Ruth; Lorigan, Paul; de Vries, Elisabeth G E; Segata, Nicola; Taams, Leonie; Papa, Sophie; Spector, Tim D; Nathan, Paul; Weersma, Rinse K; Hospers, Geke A P; Fehrmann, Rudolf S N; Bataille, Veronique; Falchi, Mario. - In: EBIOMEDICINE. - ISSN 2352-3964. - 83:(2022), pp. 10423501-10423512. [10.1016/j.ebiom.2022.104235]

Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

Rossi, Niccolò;Lee, Karla A;Bermudez, Maria V;Visconti, Alessia;Thomas, Andrew Maltez;Bolte, Laura A;Björk, Johannes R;de Ruijter, Laura Kist;Newton-Bishop, Julia;Harland, Mark;Shaw, Heather M;Harries, Mark;Sacco, Joseph;Board, Ruth;Lorigan, Paul;de Vries, Elisabeth G E;Segata, Nicola;Taams, Leonie;Papa, Sophie;Spector, Tim D;Nathan, Paul;Weersma, Rinse K;Hospers, Geke A P;Fehrmann, Rudolf S N;Bataille, Veronique;Falchi, Mario

2022-01-01

Abstract

Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor (ICI) therapy for advanced melanoma.

Scheda breve

Scheda completa

Scheda completa (DC)

	Anno di pubblicazione (Date of publication)
	
				2022
			
	Titolo del periodico (Journal title)
	
				EBIOMEDICINE
			
	DOI
	
				https://dx.doi.org/10.1016/j.ebiom.2022.104235
			
	Codice PubMed (PubMed Identifier)
	
				36007304
			
	Codice Scopus (Scopus identifier)
	
				2-s2.0-85136473914
			
	Codice WOS (WOS identifier)
	
				WOS:000861176800010
			
	Tutti gli autori
	
						Rossi, Niccolò; Lee, Karla A; Bermudez, Maria V; Visconti, Alessia; Thomas, Andrew Maltez; Bolte, Laura A; Björk, Johannes R; de Ruijter, Laura Kist; ...espandi
						
	Citazione
	
				Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma / Rossi, Niccolò; Lee, Karla A; Bermudez, Maria V; Visconti, Alessia; Thomas, Andrew Maltez; Bolte, Laura A; Björk, Johannes R; de Ruijter, Laura Kist; Newton-Bishop, Julia; Harland, Mark; Shaw, Heather M; Harries, Mark; Sacco, Joseph; Board, Ruth; Lorigan, Paul; de Vries, Elisabeth G E; Segata, Nicola; Taams, Leonie; Papa, Sophie; Spector, Tim D; Nathan, Paul; Weersma, Rinse K; Hospers, Geke A P; Fehrmann, Rudolf S N; Bataille, Veronique; Falchi, Mario. - In: EBIOMEDICINE. - ISSN 2352-3964. - 83:(2022), pp. 10423501-10423512. [10.1016/j.ebiom.2022.104235]
			
	Appare nelle tipologie:
	
				03.1 Articolo su rivista (Journal article)

File in questo prodotto:

File	Dimensione	Formato
1-s2.0-S240545692200164X-main.pdf Solo gestori archivio Descrizione: Article in press Tipologia: Versione editoriale (Publisher’s layout) Licenza: Tutti i diritti riservati (All rights reserved) Dimensione 403.78 kB Formato Adobe PDF Visualizza/Apri	403.78 kB	Adobe PDF	Visualizza/Apri
1-s2.0-S2352396422004170-main.pdf accesso aperto Tipologia: Versione editoriale (Publisher’s layout) Licenza: Creative commons Dimensione 849.21 kB Formato Adobe PDF Visualizza/Apri	849.21 kB	Adobe PDF	Visualizza/Apri